Merck Provides Update on IMPROVE-IT Trial

Tue Mar 12, 2013 8:00am EDT

* Reuters is not responsible for the content in this press release.

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130312:nBw125565a

WHITEHOUSE STATION, N.J.--(Business Wire)--
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today said
that the Data Safety Monitoring Board (DSMB) of the IMPROVE-IT trial has
completed its planned review of study data and recommended that the study
continue. 

The study design calls for the collection of 5,250 clinical endpoints. Merck
remains blinded to the actual results of this analysis and to other IMPROVE-IT
safety and efficacy data. 

IMPROVE-IT is an 18,141 patient event-driven trial, and based on the targeted
number of clinical endpoints and the rate at which events are being reported,
the trial is projected to conclude in September 2014. The IMPROVE-IT Executive
Committee and Merck will continue to monitor the progress of the study, and
Merck will update the study timeline if appropriate. No additional interim
analyses are planned. 

About Merck

Today's Merck is a global healthcare leader working to help the world be well.
Merck is known as MSD outside the United States and Canada. Through our
prescription medicines, vaccines, biologic therapies, and consumer care and
animal health products, we work with customers and operate in more than 140
countries to deliver innovative health solutions. We also demonstrate our
commitment to increasing access to healthcare through far-reaching policies,
programs and partnerships. For more information, visit www.merck.com and connect
with us on Twitter, Facebook and YouTube. 

Forward-Looking Statement

This news release includes "forward-looking statements" within the meaning of
the safe harbor provisions of the United States Private Securities Litigation
Reform Act of 1995. These statements are based upon the current beliefs and
expectations of Merck`s management and are subject to significant risks and
uncertainties. If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially from those set
forth in the forward-looking statements. 

Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest rate
and currency exchange rate fluctuations; the impact of pharmaceutical industry
regulation and health care legislation in the United States and internationally;
global trends toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent in new product
development, including obtaining regulatory approval; Merck ability to
accurately predict future market conditions; manufacturing difficulties or
delays; financial instability of international economies and sovereign risk;
dependence on the effectiveness of Merck patents and other protections for
innovative products; and the exposure to litigation, including patent
litigation, and/or regulatory actions. 

Merck undertakes no obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or otherwise. Additional
factors that could cause results to differ materially from those described in
the forward-looking statements can be found in Merck`s 2012 Annual Report on
Form 10-K and the company`s other filings with the Securities and Exchange
Commission (SEC) available at the SEC`s Internet site (www.sec.gov).

Merck
Media:
Kelley Dougherty, 908-423-4291
Skip Irvine, 267-305-5397
or
Investors:
Carol Ferguson, 908-423-4465
Justin Holko, 908-423-5088 

Copyright Business Wire 2013

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.